

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT6007025

|                                   |  |                       |
|-----------------------------------|--|-----------------------|
| <b>SUBMISSION TYPE:</b>           | NEW ASSIGNMENT                                       |                       |
| <b>NATURE OF CONVEYANCE:</b>      | ASSIGNMENT   |                       |
| <b>CONVEYING PARTY DATA</b>       |  |                       |
|                                   | <b>Name</b>  | <b>Execution Date</b> |
|                                   | SYMBIOMIX THERAPEUTICS, LLC                          | 12/29/2019            |
| <b>RECEIVING PARTY DATA</b>       |  |                       |
| <b>Name:</b>                      | LUPIN INC.   |                       |
| <b>Street Address:</b>            | HARBORPLACE TOWER, 21ST FLOOR, 111 S. CALVERT STREET |                       |
| <b>City:</b>                      | BALTIMORE  |                       |
| <b>State/Country:</b>             | MARYLAND   |                       |
| <b>Postal Code:</b>               | 21202  |                       |
| <b>PROPERTY NUMBERS Total: 19</b> |  |                       |
| <b>Property Type</b>              | <b>Number</b>  |                       |
| <b>Patent Number:</b>             | 10335390   |                       |
| <b>Application Number:</b>        | 62046731   |                       |
| <b>PCT Number:</b>                | US1548681  |                       |
| <b>Application Number:</b>        | 62101636   |                       |
| <b>Application Number:</b>        | 62126178   |                       |
| <b>Application Number:</b>        | 62126251   |                       |
| <b>Application Number:</b>        | 62169369   |                       |
| <b>Application Number:</b>        | 15170572   |                       |
| <b>PCT Number:</b>                | US1635299  |                       |
| <b>Application Number:</b>        | 62529991   |                       |
| <b>Application Number:</b>        | 13839804   |                       |
| <b>Application Number:</b>        | 13839834   |                       |
| <b>Application Number:</b>        | 13839865   |                       |
| <b>Application Number:</b>        | 16049032   |                       |
| <b>Application Number:</b>        | 16014809   |                       |
| <b>PCT Number:</b>                | US1840743  |                       |
| <b>Application Number:</b>        | 16403176   |                       |
| <b>Application Number:</b>        | 16586339   |                       |
| <b>Application Number:</b>        | 16586372   |                       |

**CORRESPONDENCE DATA****Fax Number:** (212)692-1020*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.***Phone:** 212-692-1000**Email:** IDocketing@duanemorris.com**Correspondent Name:** DUANE MORRIS LLP, ATTN: CINDY YANG**Address Line 1:** 1504 BROADWAY**Address Line 4:** NEW YORK, NEW YORK 10036-4086**ATTORNEY DOCKET NUMBER:** Y7781-00051**NAME OF SUBMITTER:** CINDY YANG**SIGNATURE:** /Cindy Yang/**DATE SIGNED:** 03/10/2020**Total Attachments: 7**

source=ExecutedConfirmatoryAssignment#page1.tif

source=ExecutedConfirmatoryAssignment#page2.tif

source=ExecutedConfirmatoryAssignment#page3.tif

source=ExecutedConfirmatoryAssignment#page4.tif

source=ExecutedConfirmatoryAssignment#page5.tif

source=ExecutedConfirmatoryAssignment#page6.tif

source=ExecutedConfirmatoryAssignment#page7.tif

## CONFIRMATORY PATENT ASSIGNMENT

This Confirmatory Patent Assignment ("Assignment") is made by and between Symbiomix Therapeutics, LLC, a Delaware limited liability company ("Assignor"), and Lupin Inc., a Delaware corporation with its principal place of business at Harborplace Tower, 21st Floor, 111 S. Calvert Street, Baltimore, Maryland 21202 ("Assignee").

WHEREAS, Assignor is the owner of all right, title and interest in and to the inventions and related U.S. and foreign Patents and applications for Patent listed in Schedule A, and the goodwill of the business in connection therewith (collectively, the "Inventions");

WHEREAS, Assignor desires to assign and transfer all right, title and interest in and to said Inventions and any Patents that may be granted therefor to Assignee, to ensure that all such right, title and interest are assigned and transferred to Assignee, and to execute and deliver this Assignment to Assignee;

WHEREAS, Assignee desires to acquire all right, title and interest in and to said Inventions and any Patents that may be granted therefor, to ensure that all right, title and interest thereto are transferred to Assignee, and to receive this Assignment from Assignor; and

WHEREAS, Assignor and Assignee agree that this Assignment is made as a distribution of assets from a disregarded subsidiary (Assignor) to its parent (Assignee) in connection with the dissolution of Assignor.

NOW, THEREFORE, in consideration of Ten U.S. Dollars (US\$10.00) and other good and valuable consideration, the receipt and sufficiency of which are hereby expressly acknowledged, Assignor hereby sells, assigns and transfers unto Assignee the entire right, title and interest for the United States and all other countries in and to said Inventions, including the aforesaid Patents and applications for Patent, all original, divisional, continuation, national/regional stage, substitute or reissue applications and patents applied for or granted therefor in the United States and all other countries, all rights under any applicable international conventions and treaties (e.g., the International Convention for the Protection of Industrial Property), including all rights of priority from the filing of said applications and all goodwill associated therewith, and all rights to sue for past, present and future infringement and to collect of damages thereof, and the U.S. Commissioner of Patents and Trademarks and relevant foreign patent offices are hereby authorized and requested to issue all patents on said Inventions or resulting therefrom to said Assignee herein, as Assignee of the entire right, title and interest therein; and the Assignor, for itself and its respective legal representatives do hereby agree and covenant, without further remuneration, to execute and deliver all Patents and all original, divisional, continuation, regional/national stage, substitute, reissue and other applications for Patent on said Inventions and all assignments thereof to said Assignee, its successors, or its assigns, to communicate to said Assignee, its successors, its assigns, or its representatives all facts known to the Assignor respecting said Inventions, whenever requested, to testify in any interferences, post-grant reviews, *inter partes* reviews, oppositions, litigations, or other legal or regulatory proceedings in which any of said Patents or applications for Patent may become involved, to

DM2\10804161.1

QB\60946862.2

**PATENT**  
**REEL: 052072 FRAME: 0353**

sign all lawful papers, make all rightful oaths, and to do generally everything necessary to assist Assignee and its respective successors, assigns and nominees to obtain patent protection for said Inventions in the United States and all other countries, the expenses incident to said applications to be borne and paid by said Assignee.


The Effective Date of this Assignment is December 29, 2019.

This Assignment is governed and interpreted by the laws of the State of Delaware without regard to conflict of law principals. Any legal action or dispute involving this Assignment shall be adjudicated in the federal or state courts in the State of Delaware.

*[signature page follows]*

IN WITNESS WHEREOF, Assignor and Assignee hereto have each duly executed and delivered this Assignment as of the Effective Date hereinabove.

**ASSIGNOR – Symbiomix Therapeutics, LLC**



Name: Sean Moriarty

Title: Secretary

**ASSIGNEE – Lupin Inc.**



Name: Sean Moriarty

Title: Secretary

**SCHEDULE A**

**PATENTS**

| <b>DM Internal Docket No.</b> | <b>Patent No. &amp; Issue Date</b>                      | <b>Title</b>  | <b>Country/Region</b> |
|-------------------------------|---|---|-----------------------|
| Y7781-00003-US                | U.S. Patent No. 10,335,390, issued July 2, 2019         | Secnidazole For Use In The Treatment Of Bacterial Vaginosis | U.S.                  |
| Y7781-00005-JP                | Japanese Patent No. 6487534, issued March 1, 2019       | Secnidazole For Use In The Treatment Of Bacterial Vaginosis | Japan                 |
| Y7781-00007-AU                | Australian Patent No. 2015-311674, issued June 21, 2018 | Secnidazole For Use In The Treatment Of Bacterial Vaginosis | Australia             |

**APPLICATIONS FOR PATENT**

| <b>DM Internal Docket No.</b> | <b>Application No. &amp; Filing Date</b>                                  | <b>Title</b>  | <b>Country/Region</b> |
|-------------------------------|---|---|-----------------------|
| Y7781-00002-US                | U.S. Provisional Application No. 62/046,731, filed September 5, 2014      | Secnidazole For Use In The Treatment Of Bacterial Vaginosis | U.S.                  |
| Y7781-00004-PCT               | PCT International Application No. PCT/US15/48681, filed September 4, 2015 | Secnidazole For Use In The Treatment Of Bacterial Vaginosis | PCT                   |
| Y7781-00006-CA                | Canadian Patent Application No. 2,959,414, filed September 4, 2015        | Secnidazole For Use In The Treatment Of Bacterial Vaginosis | Canada                |
| Y7781-00008-KR                | South Korean Patent Application No. 2017-7009154, filed September 4, 2015 | Secnidazole For Use In The Treatment Of Bacterial Vaginosis | South Korea           |
| Y7781-00009-PRO               | U.S. Provisional Application No. 62/101,636, filed January 9, 2015        | Secnidazole For Use In The Treatment Of Bacterial Vaginosis | U.S.                  |
| Y7781-00010-PRO               | U.S. Provisional Application No. 62/126,178, filed February 27, 2015      | Secnidazole For Use In The Treatment Of Melioidosis         | U.S.                  |
| Y7781-00011-PRO               | U.S. Provisional Application No. 62/126,251, filed February               | Secnidazole For Use In The Treatment Of Melioidosis         | U.S.                  |

| DM Internal Docket No. | Application No. & Filing Date  | Title  | Country/Region |
|------------------------|--|--|----------------|
|                        | 27, 2015   |  |                |
| Y7781-00012-PRO        | U.S. Provisional Application No. 62/169,369, filed June 1, 2015            | Novel Nitroimidazole Formulations And Uses Thereof                   | U.S.           |
| Y7781-00013-US         | U.S. Non-Provisional Application No. 15/170,572, filed June 1, 2016        | Novel Nitroimidazole Formulations And Uses Thereof                   | U.S.           |
| Y7781-00014-PCT        | PCT International Application No. PCT/US16/35299, filed June 1, 2016       | Novel Nitroimidazole Formulations And Uses Thereof                   | PCT            |
| Y7781-00015-CA         | Canadian Patent Application No. 2,988,082, filed June 1, 2016              | Novel Nitroimidazole Formulations And Uses Thereof                   | Canada         |
| Y7781-00016-PRO        | U.S. Provisional Application No. 62/529,991, filed July 7, 2017            | Novel Secnidazole Soft Gelatin Capsule Formulations And Uses Thereof | U.S.           |
| Y7781-00019-US         | U.S. Non-Provisional Application No. 13/839,804, filed March 15, 2013      | Methods Of Treating Disease By Administering (R)-Secnidazole         | U.S.           |
| Y7781-00020-PCT        | PCT International Application No. PCT/GB13/052344, filed September 6, 2013 | Method Of Treating Disease By Administering (R)-Secnidazole          | PCT            |
| Y7781-00021-U.S.       | U.S. Non-Provisional Application No. 13/839,834, filed March 15, 2013      | Methods Of Treating Disease By Administering (R)-Secnidazole         | U.S.           |
| Y7781-00022-PCT        | PCT International Application No. PCT/GB13/052345, filed September 6, 2013 | Method Of Treating Disease By Administering (R)-Secnidazole          | PCT            |
| Y7781-00023-PCT        | PCT International Application No. PCT/GB13/052343, filed September 6, 2013 | Method Of Treating Disease By Administering (R)-Secnidazole          | PCT            |
| Y7781-00024-US         | U.S. Non-Provisional Application No. 13/839,865, filed September 6, 2013   | Method Of Treating Disease By Administering (R)-Secnidazole          | U.S.           |

| DM Internal Docket No. | Application No. & Filing Date   | Title  | Country/Region |
|------------------------|---|--|----------------|
| Y7781-00029-US         | U.S. Non-Provisional Application No. 16/049,032, filed July 30, 2018            | Secnidazole For Use In The Treatment Of Bacterial Vaginosis  | U.S.           |
| Y7781-00030-AU         | Australian Patent Application No. 2018203882, filed June 1, 2018                | Secnidazole For Use In The Treatment Of Bacterial Vaginosis  | Australia      |
| Y7781-00031-US         | U.S. Non-Provisional Application No. 16/014,809, filed June 21, 2018            | Novel Secnidazole Soft Gelatin Formulations And Uses Thereof | U.S.           |
| Y7781-00032-PCT        | PCT International Application No. PCT/US2018/040743, filed July 3, 2018         | Novel Secnidazole Soft Gelatin Formulations And Uses Thereof | PCT            |
| Y7781-00033-AU-ADD     | Australian Patent of Addition Application No. 2018217262, filed August 15, 2018 | Secnidazole For Use In The Treatment Bacterial Vaginosis     | Australia      |
| Y7781-00037-JP-DIV1    | Japanese Patent Application No. 2019-000253, filed January 4, 2019              | Secnidazole For Use In The Treatment Bacterial Vaginosis     | Japan          |
| Y7781-00038-JP         | Japanese Patent Application No. 2018-228992, filed December 6, 2018             | Secnidazole For Use In The Treatment Bacterial Vaginosis     | Japan          |
| Y7781-00039-KR-DIV1    | South Korean Patent Application No. 2019-7006430, filed March 4, 2019           | Secnidazole For Use In The Treatment Bacterial Vaginosis     | South Korea    |
| Y7781-00041-US-DIV1    | U.S. Non-Provisional Application No. 16/403,176, filed May 3, 2019              | Secnidazole For Use In The Treatment Bacterial Vaginosis     | U.S.           |
| Y7781-00043-CA         | Canadian Patent Application No. 3,046,521, filed June 13, 2019                  | Secnidazole For Use In The Treatment Bacterial Vaginosis     | Canada         |
| Y7781-00044-KR         | South Korean Patent Application No. 2019-0088946, filed July 23, 2019           | Secnidazole For Use In The Treatment Bacterial Vaginosis     | South Korea    |
| Y7781-00045-US-DIV2    | U.S. Non-Provisional Application No.  | Secnidazole For Use In The Treatment Bacterial               | U.S.           |



| DM Internal Docket No. | Application No. & Filing Date   | Title  | Country/Region |
|------------------------|---|--|----------------|
|                        | 16/586,339, filed September 27, 2019                                      | Vaginosis  |                |
| Y7781-00046-US-DIV3    | U.S. Non-Provisional Application No. 16/586,372, filed September 27, 2019 | Secnidazole For Use In The Treatment Bacterial Vaginosis | U.S.           |